FY2024 Earnings Forecast for MMSI Issued By Zacks Research

Merit Medical Systems, Inc. (NASDAQ:MMSI) – Stock analysts at Zacks Research boosted their FY2024 earnings per share (EPS) estimates for shares of Merit Medical Systems in a research report issued on Wednesday, November 20th. Zacks Research analyst I. Bandyopadhyay now forecasts that the medical instruments supplier will post earnings of $3.36 per share for the year, up from their previous forecast of $3.31. The consensus estimate for Merit Medical Systems’ current full-year earnings is $3.36 per share. Zacks Research also issued estimates for Merit Medical Systems’ Q3 2025 earnings at $0.93 EPS, Q4 2025 earnings at $0.98 EPS, FY2025 earnings at $3.70 EPS and FY2026 earnings at $4.07 EPS.

Several other equities analysts have also commented on MMSI. Barrington Research restated an “outperform” rating and issued a $114.00 price objective on shares of Merit Medical Systems in a report on Thursday, October 31st. StockNews.com downgraded shares of Merit Medical Systems from a “buy” rating to a “hold” rating in a research note on Sunday, November 3rd. Bank of America increased their price objective on Merit Medical Systems from $92.00 to $103.00 and gave the company a “neutral” rating in a report on Monday, September 16th. Wells Fargo & Company upped their price objective on shares of Merit Medical Systems from $85.00 to $103.00 and gave the company an “equal weight” rating in a research note on Monday, September 16th. Finally, Piper Sandler restated an “overweight” rating and set a $110.00 target price (up from $100.00) on shares of Merit Medical Systems in a research report on Monday, September 9th. Three investment analysts have rated the stock with a hold rating, nine have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $103.36.

Merit Medical Systems Trading Up 0.3 %

Shares of MMSI stock opened at $105.33 on Friday. The company’s 50-day moving average price is $98.59 and its 200-day moving average price is $90.83. The stock has a market cap of $6.14 billion, a price-to-earnings ratio of 51.63, a PEG ratio of 2.61 and a beta of 0.89. The company has a current ratio of 5.36, a quick ratio of 3.82 and a debt-to-equity ratio of 0.57. Merit Medical Systems has a twelve month low of $65.46 and a twelve month high of $106.87.

Merit Medical Systems (NASDAQ:MMSI) last issued its quarterly earnings results on Wednesday, October 30th. The medical instruments supplier reported $0.86 EPS for the quarter, topping the consensus estimate of $0.80 by $0.06. Merit Medical Systems had a return on equity of 15.61% and a net margin of 9.05%. The firm had revenue of $339.85 million during the quarter, compared to analysts’ expectations of $334.60 million. During the same period in the previous year, the business earned $0.75 earnings per share. The firm’s revenue for the quarter was up 7.8% on a year-over-year basis.

Insider Buying and Selling

In other news, CFO Raul Jr. Parra sold 29,646 shares of the business’s stock in a transaction dated Tuesday, November 5th. The shares were sold at an average price of $98.02, for a total transaction of $2,905,900.92. Following the transaction, the chief financial officer now owns 16,361 shares in the company, valued at approximately $1,603,705.22. The trade was a 64.44 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director F. Ann Millner sold 12,500 shares of the firm’s stock in a transaction on Friday, November 15th. The stock was sold at an average price of $101.55, for a total value of $1,269,375.00. Following the completion of the transaction, the director now directly owns 32,391 shares of the company’s stock, valued at approximately $3,289,306.05. This trade represents a 27.85 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 3.70% of the company’s stock.

Institutional Investors Weigh In On Merit Medical Systems

A number of hedge funds have recently made changes to their positions in the company. FMR LLC raised its position in Merit Medical Systems by 70.1% in the 3rd quarter. FMR LLC now owns 1,577,246 shares of the medical instruments supplier’s stock worth $155,879,000 after purchasing an additional 649,799 shares during the last quarter. Point72 Asset Management L.P. raised its position in shares of Merit Medical Systems by 147.2% in the 2nd quarter. Point72 Asset Management L.P. now owns 634,613 shares of the medical instruments supplier’s stock valued at $54,545,000 after acquiring an additional 377,851 shares during the period. Two Sigma Advisers LP grew its holdings in shares of Merit Medical Systems by 218.9% in the 3rd quarter. Two Sigma Advisers LP now owns 445,500 shares of the medical instruments supplier’s stock valued at $44,029,000 after buying an additional 305,800 shares during the period. Iron Triangle Partners LP bought a new stake in shares of Merit Medical Systems in the third quarter worth about $25,004,000. Finally, International Assets Investment Management LLC acquired a new stake in Merit Medical Systems during the 3rd quarter worth approximately $21,156,000. Institutional investors and hedge funds own 99.66% of the company’s stock.

About Merit Medical Systems

Merit Medical Systems, Inc designs, develops, manufactures, and markets single-use medical products for interventional, diagnostic, and therapeutic procedures in the United States and internationally. It operates in two segments, Cardiovascular and Endoscopy. The company provides micropuncture kits, angiographic needles, sheaths, guide wires, and safety products; peripheral intervention, including angiography, drainage, delivery systems, and embolotherapy products; spine products, such as vertebral augmentation, radiofrequency ablation, and bone biopsy systems; oncology products; and cardiac intervention products, such as access, angiography, electrophysiology and cardiac rhythm management, fluid management, hemodynamic monitoring, hemostasis, and intervention to treat various heart conditions.